Aspyrian Therapeutics Raises $15.1M

San Diego-based Aspyrian Therapeutics, a biopharmaceuticals startup focused on precision-targeted cancer therapy, has raised $15.1M in a Series B-1 funding. The company said the funding came from private investors, including Hiroshi Mikitani, the CEO of Rakuten Inc. The company said it expects the round will reach $19M in total in the next few months. Aspyrian Therapeutics' lead compound is aimed at treating recurrent head and neck cancer, among other cancers. Miguel Garcia-Guzman is President and CEO of Aspyrian.